Peptides for Fat Loss: What Actually Works (And What Doesn't)

The peptide space for fat loss ranges from FDA-approved peptide therapy medications with mountains of clinical data to research compounds sold on hype alone. Knowing the difference can save you thousands of dollars and months of wasted effort.

Here’s what the actual science says.

Key Takeaways

• GLP-1 peptides (semaglutide, tirzepatide) have the strongest fat loss evidence — 15-22% body weight reduction in large clinical trials, with roughly 74% of weight lost coming from fat mass [1][4]
• Tesamorelin is the only FDA-approved peptide specifically for fat reduction, though its approval is limited to HIV-associated lipodystrophy [5]
• AOD-9604 showed modest results in trials — about 2.6 kg over 12 weeks — and never made it past Phase 2b [7]
• Growth hormone secretagogues (CJC-1295, ipamorelin) may improve body composition indirectly, but the direct fat loss data is thin

Table of Contents

1. How Peptides Burn Fat: Three Different Mechanisms
2. GLP-1 Receptor Agonists: The Heavy Hitters
3. Tesamorelin: The Visceral Fat Specialist
4. AOD-9604: The GH Fragment
5. Growth Hormone Peptides: CJC-1295, Ipamorelin, and Others
6. Realistic Timelines: What to Actually Expect
7. Side Effects and Safety
8. FAQ
9. Sources

How Peptides Burn Fat: Three Different Mechanisms

Not all fat-loss peptides work the same way. Understanding the mechanism matters because it determines what kind of results you can realistically expect.

Appetite Suppression (GLP-1 Pathway)

GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and act on brain regions that control hunger. You eat less. You feel full faster. The caloric deficit does the heavy lifting.

This isn’t a “fat burner” in the traditional sense. It’s a powerful appetite brake. But the clinical results speak for themselves — they produce more fat loss than any other peptide class by a wide margin [1].

Direct Lipolysis (Growth Hormone Pathway)

Growth hormone stimulates the breakdown of stored triglycerides in fat cells. Peptides that boost GH levels — like CJC-1295 and ipamorelin — aim to tap into this pathway. Tesamorelin works here too, specifically targeting visceral fat.

The effect is real but more modest than the GLP-1 approach. You’re not going to lose 15% of your body weight through GH-mediated lipolysis alone [5][6].

Fat Oxidation (GH Fragment Approach)

AOD-9604 is a fragment of human growth hormone (amino acids 177-191) designed to stimulate fat oxidation without the metabolic side effects of full GH. The idea is that you get fat burning without blood sugar disruption. In practice, the results have been underwhelming compared to other options [7].

GLP-1 Receptor Agonists: The Heavy Hitters

If we’re being honest about what works best for fat loss, the conversation starts and ends with GLP-1 receptor agonists — the same peptides for weight loss that have dominated clinical trials. The data is overwhelming.

Semaglutide (Wegovy)

The STEP 1 trial enrolled 1,961 adults with obesity. After 68 weeks, the semaglutide group lost an average of 14.9% of body weight compared to 2.4% for placebo [1].

But here’s what matters for fat loss specifically: a DXA substudy of 140 participants showed that semaglutide led to greater reductions in fat mass than lean body mass. The proportion of lean mass relative to total body mass actually increased during treatment [2]. That’s a meaningful distinction — you’re losing fat, not just weight.

Total fat mass dropped significantly, and visceral fat (the dangerous kind wrapped around organs) decreased substantially more with semaglutide than placebo [2].

Tirzepatide (Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist, and the results are even more striking. In the SURMOUNT-1 trial, the 15 mg dose produced 20.9% body weight reduction at 72 weeks versus 3.1% for placebo [3].

The body composition data is particularly interesting. A DXA substudy found a 33.9% reduction in mean total body fat mass with tirzepatide. About 74% of total weight lost was fat mass and 26% was lean mass — a ratio similar to what you’d see with diet and exercise alone [4]. Visceral fat mass dropped significantly too.

What GLP-1s Won’t Do

These aren’t magic. You’ll still lose some lean mass alongside fat. Resistance training during treatment helps preserve muscle. And when people stop the medication, weight regain is common — the STEP 1 trial extension showed participants regained about two-thirds of lost weight within a year of stopping [1].

They also come with gastrointestinal side effects (nausea, vomiting, diarrhea) that affect 40-70% of users in the first weeks. Most of this improves with dose titration [1][3].

Tesamorelin: The Visceral Fat Specialist

Tesamorelin (brand name Egrifta) is the only peptide with specific FDA approval for fat reduction — though that approval is narrowly for HIV-associated lipodystrophy, not general obesity.

It’s a synthetic analog of growth hormone-releasing hormone (GHRH). It tells your pituitary to release more GH, which in turn mobilizes visceral fat.

The Clinical Data

In a randomized, double-blind trial of 404 adults with HIV and excess abdominal fat, six months of daily tesamorelin reduced visceral adipose tissue by 10.9% compared to 0.6% for placebo [5]. That’s statistically significant but far more modest than what GLP-1s achieve for total fat loss.

A follow-up study showed that tesamorelin specifically reduced visceral fat without significantly affecting subcutaneous fat. It also improved trunk fat and waist circumference [5][6].

IGF-1 levels increased by about 81 ng/mL on average during treatment, confirming the GH axis was being stimulated [6].

Where Tesamorelin Fits

Tesamorelin makes the most sense for people whose primary concern is visceral fat — the metabolically active fat around organs that drives insulin resistance and cardiovascular risk. It’s not a weight loss drug in the traditional sense. Most patients don’t see dramatic changes on the scale.

The standard protocol is 2 mg injected subcutaneously once daily. It’s typically prescribed in 6-month cycles [5].

Limitations

Tesamorelin raises IGF-1, which is theoretically concerning for cancer risk with long-term use. Current evidence doesn’t show increased cancer rates in the HIV population studied, but the long-term data in otherwise healthy adults is limited [6].

When you stop tesamorelin, visceral fat tends to return to baseline within 3-6 months. It’s not a permanent fix.

AOD-9604: The GH Fragment

AOD-9604 gets a lot of attention in the peptide community, but the clinical reality is less impressive than the marketing suggests.

What It Is

AOD-9604 is the C-terminal fragment of human growth hormone (amino acids 177-191). Researchers isolated this fragment because it appeared to stimulate lipolysis without affecting blood sugar or IGF-1 levels — essentially trying to get the fat-burning benefits of GH without the downsides [7].

The Trial Results

The most cited clinical evidence comes from a 12-week Phase 2b randomized trial. Subjects receiving 1 mg/day of oral AOD-9604 lost an average of 2.6 kg (about 5.7 lbs), while the placebo group lost 0.8 kg (1.8 lbs) [7][8].

That’s a net difference of roughly 1.8 kg (4 lbs) over three months. Compare that to semaglutide’s 14.9% body weight reduction (roughly 15 kg in a person who starts at 100 kg) over 68 weeks [1]. The scale of effect isn’t in the same league.

The trial tested doses of 0.25 mg, 0.5 mg, and 1 mg daily. Only the 1 mg dose showed statistically significant results [8].

Why Development Stopped

AOD-9604 never progressed beyond Phase 2b clinical trials. The developing company, Metabolic Pharmaceuticals, essentially shelved the program. No Phase 3 trial was ever completed. No FDA approval was ever sought for weight loss [7].

This doesn’t mean it’s dangerous — the safety profile was actually clean. But the modest effect size likely made it commercially unviable, especially as GLP-1 drugs entered the picture.

The Honest Assessment

AOD-9604 might produce a small amount of fat loss. But “small” is the key word. If you’re looking for meaningful fat reduction, the evidence doesn’t support AOD-9604 as a primary tool. It’s sometimes used as part of a broader peptide stack, but even then, attributing results specifically to AOD-9604 is difficult.

It’s not FDA-approved for any indication. Most AOD-9604 available today comes from compounding pharmacies or research chemical suppliers, with the quality control issues that come with that territory.

Growth Hormone Peptides: CJC-1295, Ipamorelin, and Others

Growth hormone secretagogues (GHS) are peptides that stimulate your pituitary gland to release more of your own growth hormone. The two most commonly used for body composition are CJC-1295 and ipamorelin — a GHRH analog paired with a ghrelin receptor agonist.

How They Affect Fat

Growth hormone promotes lipolysis — the breakdown of stored fat for energy. Higher GH levels increase the rate at which your body mobilizes fat, particularly during fasting and exercise [9].

In a clinical trial, CJC-1295 with DAC (drug affinity complex) produced sustained, dose-dependent increases in GH and IGF-1 levels. At doses of 30-60 mcg/kg, IGF-1 remained elevated above baseline for up to 28 days after a single injection [9].

Ipamorelin is notable for its selectivity — it stimulates GH release without raising cortisol, prolactin, or ACTH levels, even at doses 200-fold above the effective dose for GH release [10]. This matters because cortisol promotes fat storage, so a GH secretagogue that doesn’t raise cortisol has a theoretical advantage.

The Missing Piece: Direct Fat Loss Data

Here’s what the GH peptide community often glosses over: there are no large, randomized controlled trials showing that CJC-1295 or ipamorelin specifically reduce body fat percentage in otherwise healthy adults.

We know they raise GH. We know GH promotes lipolysis. But the leap from “higher GH levels” to “clinically meaningful fat loss” hasn’t been demonstrated in rigorous trials for these specific compounds.

The body composition improvements reported by clinics and patients are real, but they’re typically seen alongside exercise programs and dietary changes — making it hard to isolate the peptide’s contribution [9][10].

Where GH Peptides Might Help

GH peptides probably work best as part of a comprehensive approach. They may:

• Improve the ratio of fat loss to muscle loss during a caloric deficit — GH is protein-sparing
• Enhance recovery from exercise, allowing more training volume
• Improve sleep quality (particularly with nighttime dosing), which itself supports better body composition
• Provide modest fat-mobilizing effects that compound over months

They’re not a substitute for GLP-1 agonists if pure fat loss is your goal. Think of them as body composition optimizers rather than fat loss drugs.

Realistic Timelines: What to Actually Expect

One of the biggest mistakes people make is expecting peptide-level fat loss on a supplement timeline. Here’s what the evidence actually shows:

GLP-1 Agonists (Semaglutide, Tirzepatide)

• Weeks 1-4: Dose titration phase. Modest weight loss (1-2 kg) mostly from reduced food intake
• Months 2-4: Fat loss accelerates. Expect 5-8% body weight reduction
• Months 6-12: Most patients reach 12-20% body weight reduction at stable doses
• Peak effect: Around 68-72 weeks in clinical trials [1][3]

Tesamorelin

• Month 1-2: GH and IGF-1 levels increase. Minimal visible changes
• Month 3-6: Visceral fat reduction becomes measurable (around 10-11% reduction by month 6) [5]
• Beyond 6 months: Continued maintenance. Most protocols run 6-month cycles

AOD-9604

• Weeks 1-8: Minimal measurable change
• Weeks 8-12: Modest fat loss (2-3 kg above placebo, at best) [7]
• Beyond 12 weeks: Limited long-term data available

GH Peptides (CJC-1295 + Ipamorelin)

• Weeks 1-4: GH and IGF-1 levels rise. Sleep quality may improve. Body composition changes are minimal
• Months 2-3: Some patients report reduced waist circumference and improved muscle definition
• Months 3-6: Most noticeable body composition changes, especially with consistent training
• No large trial data to give precise numbers

Side Effects and Safety

GLP-1 Agonists

The most common side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) in the STEP 1 trial [1]. Most symptoms improve with dose titration. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumor risk (seen in rodents, unconfirmed in humans).

Tesamorelin

Generally well tolerated. Common side effects include injection site reactions, joint pain, and peripheral edema. The main theoretical concern is chronic IGF-1 elevation and potential cancer risk with long-term use [5][6].

AOD-9604

The Phase 2b trial reported a clean safety profile. No significant adverse events above placebo. No effect on blood glucose or IGF-1 levels [7][8]. The limited trial data means rare side effects could still be undiscovered.

GH Peptides (CJC-1295, Ipamorelin)

Common side effects include flushing, headache, dizziness, and injection site irritation. Water retention and tingling/numbness in extremities can occur. CJC-1295 with DAC was associated with one death during clinical trials, which led to the discontinuation of that particular program [9][11]. The no-DAC version (Mod GRF 1-29) has a shorter half-life and is generally considered to carry less risk.

Ipamorelin specifically has one of the cleanest safety profiles among GH secretagogues due to its selectivity — no cortisol or prolactin elevation even at very high doses [10].

FAQ

What is the most effective peptide for fat loss?▼

Based on clinical trial data, tirzepatide (Zepbound) produces the largest fat mass reduction — about 33.9% reduction in total body fat at the 15 mg dose over 72 weeks [4]. Semaglutide (Wegovy) is a close second with 14.9% total body weight loss, the majority from fat [1][2]. Both are FDA-approved for weight management.

Can you lose belly fat with peptides?▼

Yes, specifically visceral belly fat. Tesamorelin reduced visceral adipose tissue by 10.9% over six months in clinical trials [5]. GLP-1 agonists also significantly reduce visceral fat — the SURMOUNT-1 DXA substudy confirmed substantial visceral fat reduction with tirzepatide [4]. For stubborn subcutaneous belly fat, GLP-1 agonists with a caloric deficit remain the most evidence-based approach.

Is AOD-9604 worth it for fat loss?▼

The evidence is underwhelming. The best clinical trial showed only 2.6 kg of weight loss over 12 weeks at the optimal dose [7]. Development was abandoned after Phase 2b, and no FDA approval was pursued. It’s not dangerous based on available data, but the fat loss effect is modest compared to other options. It may have a role as part of a stack, but don’t expect dramatic results from AOD-9604 alone.

Do you need a prescription for fat loss peptides?▼

Semaglutide (Wegovy) and tirzepatide (Zepbound) require a prescription and are FDA-approved for weight management. Tesamorelin (Egrifta) requires a prescription but is only FDA-approved for HIV lipodystrophy. CJC-1295, ipamorelin, and AOD-9604 are not FDA-approved for any indication and are typically obtained through compounding pharmacies with a prescription or research chemical suppliers without one. We strongly recommend working with a licensed provider for any peptide therapy.

How long do you need to take peptides for fat loss?▼

Most fat loss peptides require months of consistent use. GLP-1 agonists show peak effects at 68-72 weeks in trials, and weight regain is common after stopping [1][3]. Tesamorelin is typically prescribed in 6-month cycles [5]. GH peptides like CJC-1295 and ipamorelin are commonly used in 8-16 week cycles. The uncomfortable truth is that most peptide-mediated fat loss requires ongoing treatment to maintain — they’re managing a chronic condition, not providing a one-time fix.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 PubMed: 33567185

2. Batterham RL, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Diabetes Obes Metab. 2021. PMC8089287

3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 (SURMOUNT-1)

4. Look ARH, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. PubMed: 39996356

5. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. (Tesamorelin Phase 3)

6. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomized clinical trial. JAMA. 2014;312(4):380-389.

7. Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and humans. Endocrinology. 2001. (AOD-9604 preclinical/clinical)

8. Metabolic Pharmaceuticals. Phase 2b clinical trial of AOD9604 for obesity. BioSpace report, 2006. biospace.com

9. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed: 16352683

10. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed: 9849822

11. CJC-1295. Wikipedia. Accessed March 2026. en.wikipedia.org

12. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMC5632578